prof. dr. Fritz Offner
- ORCID iD
-
0000-0003-4690-3603
Show
Sort by
-
- Journal Article
- A1
- open access
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells
-
Pan-cancer blood plasma cell-free RNA profiles reveal cancer type and patient-specific changes
-
- Journal Article
- A1
- open access
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL : a multicentre, non-randomised, open-label phase 2 study
-
- Miscellaneous
- open access
Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustion
-
- Journal Article
- A1
- open access
RNA extraction method impacts quality metrics and sequencing results in formalin-fixed, paraffin-embedded tissue samples
-
Isolated amyloidosis of the gastro-intestinal tract
-
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma
-
Five-year results and overall survival update from the phase 3 randomized study AUGMENT : lenalidomide plus rituximab (R-2) vs rituximab plus placebo in patients with relapsed/refractory indolent Non-Hodgkin lymphoma
-
CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell engaging bispecific antibody glofitamab in relapsed or refractory B-cell Non-Hodgkin lymphoma
-
Subcutaneous epcoritamab in combination with rituximab plus lenalidomide (R-2) for first-line treatment of follicular lymphoma : initial results from phase 1/2 trial